Trimetrexate in untreated and previously treated patients with metastatic breast cancer: A Cancer and Leukemia Group B study Journal Article


Authors: Dawson, N. A.; Costanza, M. E.; Korzun, A. H.; Clamon, G. H.; Pollak, M.; Vogelzang, N. J.; Carey, R. W.; Norton, L.
Article Title: Trimetrexate in untreated and previously treated patients with metastatic breast cancer: A Cancer and Leukemia Group B study
Abstract: Twenty‐two patients with previously untreated metastatic breast cancer and nineteen patients with refractory metastatic breast cancer were treated with trimetrexate (TMTX). Patients received TMTX 8 mg/m2/day if previously treated or 12 mg/m2/day if previously untreated, both given by intravenous bolus days 1–5, every 21 days. None of the patients previously treated for metastatic disease responded to TMTX. There was one partial responder among the 22 patients with previously untreated metastatic disease. The primary toxicity was hematologic and occurred more frequently in patients with a pleural effusion, low serum protein or albumin, or poor performance status. There were three toxic deaths. The study for previously untreated patients required cyclo‐phosphamide, doxorubicin, and 5‐fluorouracil (CAF) after 4 cycles of TMTX. This study design for previously untreated patients allows the Cancer and Leukemia Group B (CALGB) to prospectively evaluate the activity of new agents in “chemotherapy‐sensitive” metastatic breast cancer. Copyright © 1991 Wiley‐Liss, Inc., A Wiley Company
Keywords: adult; clinical article; aged; doxorubicin; fluorouracil; antineoplastic agents; liver neoplasms; metastasis; breast cancer; bone marrow suppression; breast; antineoplastic combined chemotherapy protocols; drug administration schedule; cyclophosphamide; breast neoplasms; carcinoma; quinazolines; intravenous drug administration; hematologic diseases; middle age; trimetrexate; human; female; priority journal; article; support, non-u.s. gov't; support, u.s. gov't, p.h.s.
Journal Title: Medical and Pediatric Oncology
Volume: 19
Issue: 4
ISSN: 0098-1532
Publisher: Wiley Liss  
Date Published: 1991-01-01
Start Page: 283
End Page: 288
Language: English
DOI: 10.1002/mpo.2950190413
PUBMED: 1829134
PROVIDER: scopus
DOI/URL:
Notes: Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Larry Norton
    758 Norton